Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
4basebio UK Societas (GB:4BB)
LSE:4BB
RESEARCH TOOLSreports
Holding GB:4BB?
Track your performance easily
4BB Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range520.00p - 1,820.00p
Previous Close1,300p
Volume2.00
Average Volume (3M)9.51K
Market Cap
£201.21M
Enterprise Value196.62M
Total Cash (Recent Filing)£4.59M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.29
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding12,319,473
10 Day Avg. Volume48,297
30 Day Avg. Volume9,506
Standard Deviation0.13
R-Squared0.13
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4642.86
Price to Sales (P/S)452.41
Price to Cash Flow (P/CF)-26.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4basebio UK Societas News
PremiumCompany Announcements
4basebio CEO’s Share Transfer Keeps Stake Intact
PremiumCompany Announcements
4basebio PLC Sees Shift in Voting Rights
PremiumCompany Announcements
4basebio UK Societas Reports Major Voting Rights Update
PremiumCompany Announcements
4basebio UK Societas Sees Major Shift in Shareholding
PremiumCompany Announcements
4basebio PLC Reports Major Shift in Voting Rights
PremiumCompany Announcements
4basebio Shareholder Deutsche Balaton Reduces Stake
PremiumCompany Announcements
4basebio Shareholder Structure Sees Major Shift
PremiumCompany Announcements
4basebio PLC Announces Change in Shareholder Voting RightsOptions Prices
Currently, No data available
---
Ownership Overview
4BB FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 520.00p and its highest was 1820.00p in the past 12 months.
What is 4basebio UK Societas’s market cap?
Currently, no data Available
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s upcoming earnings report date is May 07, 2025 which is in 166 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on Sep 27, 2024. The company reported -0.45p earnings per share for the quarter, missing the consensus estimate of N/A by -0.45p.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Overvalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 15,477,395 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -0.45p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in GB:4BB
---
4basebio UK Societas Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth £7.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.22%
Trailing 12-Months
Company Description
4basebio UK Societas
4basebio UK Societas is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process to manufacture Good Manufacturing Practice grade DNA, suitable for use in gene therapies and DNA vaccines.
---
Technical Analysis
---